Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins.
The nasal cavity of a rodent is lined by an epithelium organized into distinct regional domains responsible for specific physiological functions. Aggregates of nasal lymphoid tissue (NALT) located at the base of the nasal cavity are believed to be sites of induction of mucosal immune responses to airborne antigens. The epithelium overlying NALT contains M cells which are specialized for the transcytosis of immunogens, as demonstrated in other mucosal tissues. We hypothesized that NALT M cells are characterized by distinct glycoconjugate receptors which influence antigen uptake and immune responses to transcytosed antigens. To identify glycoconjugates that may distinguish NALT M cells from other cells of the respiratory epithelium (RE), we performed lectin histochemistry on sections of the hamster nasal cavity with a panel of lectins. Many classes of glycoconjugates were found on epithelial cells in this region. While most lectins bound to sites on both the RE and M cells, probes capable of recognizing alpha-linked galactose were found to label the follicle-associated epithelium (FAE) almost exclusively. By morphological criteria, the FAE contains >90% M cells. To determine if apical glycoconjugates on M cells were accessible from the nasal cavity, an M-cell-selective lectin and a control lectin in parallel were administered intranasally to hamsters. The M-cell-selective lectin was found to specifically target the FAE, while the control lectin did not. Lectin bound to M cells in vivo was efficiently endocytosed, consistent with the role of M cells in antigen transport. Intranasal immunization with lectin-test antigen conjugates without adjuvant stimulated induction of specific serum immunoglobulin G, whereas antigen alone or admixed with lectin did not. The selective recognition of NALT M cells by a lectin in vivo provides a model for microbial adhesin-host cell receptor interactions on M cells and the targeted delivery of immunogens to NALT following intranasal administration.
Giannasca
P J
PJ
OraVax, Inc., Cambridge, Massachusetts 02139, USA. pgiannas@oravax.com
Boden
J A
JA
Monath
T P
TP
D000281:Administration, Intranasal; D000818:Animals; D000941:Antigens / Q000008:administration & dosage* / Q000276:immunology; D006224:Cricetinae; D005260:Female; D005697:Galactosides / Q000302:isolation & purification / Q000378:metabolism; D006001:Glycoconjugates / Q000302:isolation & purification* / Q000378:metabolism; D006651:Histocytochemistry; D037102:Lectins / Q000008:administration & dosage* / Q000378:metabolism; D008221:Lymphoid Tissue / Q000737:chemistry / Q000166:cytology / Q000276:immunology*; D008647:Mesocricetus; D009297:Nasal Mucosa / Q000737:chemistry / Q000166:cytology / Q000276:immunology*; D011485:Protein Binding; D014611:Vaccination / Q000379:methods*; D018998:Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate / Q000008:administration & dosage / Q000276:immunology
D000941:Antigens; D005697:Galactosides; D006001:Glycoconjugates; D037102:Lectins; D018998:Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate